South Korea's drug watchdog to review U.S. Tylenol claim
Reuters
Sep 24
South Korea's drug watchdog to review U.S. Tylenol claim
SEOUL, Sept 24 (Reuters) - South Korea's drug watchdog said on Tuesday it would seek information from relevant companies after a U.S. government announcement on Tylenol, adding that it planned to review opinions and documents they provided.
On Monday, President Donald Trump linked autism to childhood vaccine use and the use of popular pain medication Tylenol by pregnant women, elevating to the forefront of U.S. health policy claims unsupported by scientific evidence.
(Reporting by Hyunjoo Jin and Heekyong Yang; Editing by Clarence Fernandez)
((Heekyong.Yang@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.